This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davalos, V. Articles by Arango, D. Search for Related Content PubMed PubMed Citation Articles by Davalos, V. Articles by Arango, D.

EPHB4 and Survival of Colorectal Cancer Patients

¹ Molecular Oncology Program and ² Functional Genomics Program, Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center, Vall d'Hebron Hospital Research Institute and ³ Translational Research Laboratory, Institut Catala d'Oncologia, Barcelona, Spain; ⁴ Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York; and ⁵ Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

Requests for reprints: Diego Arango, Functional Genomics Program, Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center, Vall d'Hebron Hospital Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain. Phone: 34-93-274-6739; Fax: 34-93-489-4040; E-mail: darango{at}ir.vhebron.net.

The family of receptor tyrosine kinases EPH and their Ephrin ligands regulate cell proliferation, migration, and attachment. An important role in colorectal carcinogenesis is emerging for some of its members. In this study, we evaluate the role of EPHB4 in colorectal cancer and its value as a prognostic marker. EPHB4 levels were assessed by immunohistochemical staining of tissue microarrays of 137 colorectal tumors and aberrant hypermethylation of the EPHB4 promoter was investigated using methylation-specific PCR. We found that EPHB4 expression is frequently reduced or lost in colorectal tumors. Patients with low EPHB4 tumor levels had significantly shorter survival than patients in the high EPHB4 group (median survival, 1.8 and >9 years, respectively; P < 0.01, log-rank test), and this finding was validated using an independent set of 125 tumor samples. In addition, we show that EPHB4 promoter hypermethylation is a common mechanism of EPHB4 inactivation. Moreover, reintroduction of EPHB4 resulted in a significant reduction in the clonogenic potential of EPHB4-deficient cells, whereas abrogation of EPHB4 in cells with high levels of this receptor lead to a significant increase in clonogenicity. In summary, we identified EPHB4 as a useful prognostic marker for colorectal cancer. In addition, we provide mechanistic evidence showing that promoter methylation regulates EPHB4 transcription and functional evidence that EPHB4 can regulate the long-term clonogenic potential of colorectal tumor cells, revealing EPHB4 as a potential new tumor suppressor gene in colorectal cancer. (Cancer Res 2006; 66(18): 8943-8)

This article has been cited by other articles:

				H. Dopeso, S. Mateo-Lozano, R. Mazzolini, P. Rodrigues, L. Lagares-Tena, J. Ceron, J. Romero, M. Esteves, S. Landolfi, J. Hernandez-Losa, et al. The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis Cancer Res., September 15, 2009; 69(18): 7430 - 7438. [Abstract] [Full Text] [PDF]

				S.-T. Chiu, K.-J. Chang, C.-H. Ting, H.-C. Shen, H. Li, and F.-J. Hsieh Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells Carcinogenesis, September 1, 2009; 30(9): 1475 - 1486. [Abstract] [Full Text] [PDF]

				S. R. Kumar, J. S. Scehnet, E. J. Ley, J. Singh, V. Krasnoperov, R. Liu, P. K. Manchanda, R. D. Ladner, D. Hawes, F. A. Weaver, et al. Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer Progression Cancer Res., May 1, 2009; 69(9): 3736 - 3745. [Abstract] [Full Text] [PDF]

				M. Lackmann and A. W. Boyd Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity? Sci. Signal., April 15, 2008; 1(15): re2 - re2. [Abstract] [Full Text] [PDF]

				N. K. Noren and E. B. Pasquale Paradoxes of the EphB4 Receptor in Cancer Cancer Res., May 1, 2007; 67(9): 3994 - 3997. [Abstract] [Full Text] [PDF]